Articles tagged with Cancer Medication
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
Researchers discovered a new biomarker, inactive AMPK (lo-P-AMPK), that may predict immune evasion in lung cancer. The finding could enable better personalized care for lung cancer patients by identifying those most likely to benefit from immunotherapies.
Researchers have identified genetic mutations in genes CBP and p300 that drive radiation resistance in head and neck tumors. Inhibiting these proteins with certain drugs makes tumor cells more susceptible to radiotherapy.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
Researchers found that inhibiting the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia. The study used murine models and human patient-derived xenografts to evaluate the anti-leukemic capacity of 5Z7O, which showed synergistic induction of cytotoxicity when combined with dexamethasone.
Researchers from Kazan Federal University have developed a gene-cell preparation that uses membrane vesicles to target and kill cancer cells. The technology has shown promise in treating various types of cancer, including breast, lung, and colon cancer.
Metastases in malignant melanoma can use an alternative process to access the circulatory system, where a blood vessel divides into two parallel vessels. This finding challenges traditional research on tumor growth and may lead to new treatment options for metastatic cancer.
A Singapore clinical trial has introduced a new way to treat advanced hepatocellular carcinoma by combining nivolumab, an immunotherapy drug, with yttrium-90 resin microspheres radioembolisation. The study shows promising results in treating intermediate and advanced HCC, with an overall response rate of 30.6%.
Researchers developed two model systems to study peritoneal metastases from colorectal cancer patients. Biomarkers were identified, including severe mutations of the BRCA2 gene, which predict therapy response. These findings offer new hope for treating advanced cases.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
ImCheck's ICT01 selectively activates Vγ9Vδ2 T cells through all three isoforms of BTN3A, overcoming prior limitations. The therapy demonstrates anti-tumor activity in solid and hematologic cancer models.
A new study from MIT reveals that calorie-restricted diets slow tumor growth in mice by reducing fatty acid availability, while ketogenic diets have limited effect. The findings offer insight into how dietary interventions might be combined with existing or emerging drugs to help patients with cancer.
Researchers at University of Pittsburgh and Prairie View A&M University developed an algorithm to repurpose cancer drugs for pulmonary hypertension, a devastating lung disease. Two compounds improved human cells and rodent markers, supporting broader drug-repurposing platform use.
Researchers at MIT have developed a new approach to treat cancer by combining chemotherapy, tumor injury, and immunotherapy. In mouse studies, the treatment eliminated tumors completely in nearly half of the mice and showed promise against various types of cancer.
Two new studies examine rising cancer drug spending in the US, finding that many patients receive treatments with no documented overall survival benefit. The studies suggest that the combination of regulatory, pricing, and reimbursement policies contributes to wasteful healthcare spending.
Researchers discovered that leukemia cells immediately unresponsive to treatment have high levels of SAMHD1, while those with acquired resistance use the enzyme DCK to activate nucleoside analogues. This finding may lead to better cancer therapies.
Researchers at University of Virginia Health System have discovered a new treatment target for osteoporosis and bone loss from rheumatoid arthritis. A cellular protein called ELMO1 promotes the activity of osteoclasts, which break down bone, leading to excessive bone degradation.
Scientists from Duke-NUS and Xylonix are developing novel immunotherapies for treating cancer and COVID-19 complications using liposome drug formulations. The goal is to enhance the uptake of 010DS-Zn by tumours for improved therapeutic effects.
Researchers created polymersomes that target highly invasive cancer cells, delivering anticancer drugs and preventing metastasis. The nanomachines showed strong antitumor effects in breast cancer models, inhibiting lung metastasis and prolonging survival.
Researchers conducted a functional test to identify effective therapies for advanced hematological cancers, achieving significant positive outcomes with 56 patients receiving individually tailored treatment. The study demonstrates the clinical feasibility and efficacy of personalized medicine in breaking resistance to prior therapies.
A phase II clinical trial has shown that the DNA alkylation drug DM-CHOC-PEN improved survival in adolescent and young adult patients with central nervous system cancers. The treatment was well-tolerated, with no severe toxicities observed, and showed potential for combination with other treatments.
Researchers found that a cancer chemotherapy drug can restore memory and cognitive function in mice with Alzheimer’s disease by inhibiting blood vessel growth. The study suggests repurposing approved anti-cancer drugs as treatments for Alzheimer’s disease, potentially shortening clinical development time.
University of Delaware chemical engineer Catherine Fromen aims to improve the delivery of therapeutic medicines to the body by studying how they interact with mucosal interfaces. Her research focuses on designing medicines that can overcome natural defenses in the lungs and gut, with potential applications for diseases such as lung can...
Researchers at the University of Virginia Health System have identified 14 genes that can cause and three that can prevent weight gain, offering a promising lead in developing new treatments for obesity. The findings were made using a worm model of obesity and automation to test hundreds of genes.
A new study reveals that high levels of polyunsaturated fatty acids in liver cells are associated with resistance to hepatitis C virus infection. Lipid peroxidation occurs on PUFA-enriched membranes where viral replication machinery is anchored, ultimately shutting off its ability to replicate the viral genome.
A new analysis suggests that most never-smokers' lung tumors have actionable mutations, making them treatable with existing FDA-approved drugs. The study found that 78-92% of lung cancers in patients who have never smoked can be targeted with precision drugs.
Researchers have developed a new cancer photodrug that can treat deep-seated tumors more effectively and with reduced toxicity. Copper cysteamine photosensitizers allow the production of reactive oxygen species to kill cancer cells, minimizing damage to healthy cells.
Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.
A new study at Ohio State University's Comprehensive Cancer Center is using rapid autopsies to gather biological samples after death to better understand how cancer cells overcome different treatments. This approach has already led to novel findings about drug resistance mechanisms, including the recent approval of a targeted therapy f...
Researchers have identified a way to restore the effectiveness of drugs in clinical trials for treating AML by using human alpha(1)-acid glycoprotein (AGP) as a 'decoy' to bind and inhibit FLT3-mutated leukemia cells. The approach has potential for improving patient outcomes, particularly for patients with FLT3-mutated AML.
A study by Weill Cornell Medicine identified Oct2 as the key determinant of B-cell humoral immune response, suggesting that the destiny of antibody-producing cells is predetermined. This discovery may lead to new insights into tissue development and cancer development.
Patients with certain gene mutations are at high risk of fatal chemotherapy toxicity, with a 25-times increased risk detected in those with uncommon DPYD variants. The study suggests that adding pre-treatment screening may help prevent avoidable deaths without interrupting standard care.
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
The University of Helsinki-led research project partners with UCSF to develop new therapies targeting MYC cancer gene vulnerabilities. The goal is to create next-generation cancer drugs that selectively kill cancer cells while leaving normal cells unharmed.
Bioengineer Kevin McHugh is developing a platform to improve the performance of injectable drugs, which often release diminishing amounts of medication over time. The goal is to create predictable, long-lasting delivery systems for better patient outcomes and reduced dosing frequency.
Researchers have developed an AI-powered platform that allows scientists to grow virtual tumors and optimize nanoparticle designs using artificial intelligence. The new EVONANO platform has the potential to improve targeted cancer treatments, enabling personalized therapies for individual patients.
Researchers find PADI4 and HIF-1 proteins work together to deliver oxygen and nutrients to tumors, allowing them to grow. The discovery provides new avenues for anti-cancer therapies targeting blood vessel development.
Researchers at Weill Cornell Medicine identified club cell factors that inhibit immunosuppressive cells in tumors, leading to increased antitumor T cells and improved effectiveness of PD1 immunotherapy. A
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.
A new trial run by UCL researchers shows promise in slowing the regrowth of tumors among some bowel cancer patients. The drug adavosertib was found to delay tumour growth by about two months on average and had relatively few side effects, particularly in left-sided/rectal tumours.
Researchers at MD Anderson Cancer Center presented new findings on novel therapeutic approaches, including cell therapy for solid tumors and antibody drug conjugates targeting TROP2. The therapies achieved partial responses in six patients, with an overall response rate of 35.3% and disease control rate of 70.6%.
Eosinophils, a type of white blood cell, play a crucial role in destroying malignant tumors by recruiting T-cells and releasing destructive proteins. The study, published in Cancer Research, reveals that eosinophils combat cancer effectively but require the help of T-cells to do so.
Scientists at the University of Birmingham have discovered a new pathway involving tetraspanin protein TSPAN6 that makes anti-EGFR drugs less effective in bowel cancer patients. The research findings could lead to better identification of patients who can benefit from these treatments.
Researchers have shown that physical exercise normalizes metabolic abnormalities caused by cancer, reducing anemia and associated fatigue. Exercise regenerates metabolism, blunting excessive blood cell formation and destruction, leading to improved tolerance of chemotherapy and radiotherapy.
A multicenter clinical trial tested the use of lurbinectedin in patients with small cell lung cancer (SCLC), which did not meet its primary end point of overall survival. However, the combination of lurbinectedin and doxorubicin was found to be active in patients with SCLC after one prior platinum-based chemotherapy.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
A new study suggests that T cell therapy alone or combined with cancer drug nivolumab is safe and persistent in attacking Hodgkin's lymphoma cells. The treatment showed promising results in patients with relapsed or refractory HL, offering a potential option for those who do not respond to checkpoint inhibitors.
Researchers at Tampere University identified a specific population of treatment-resistant cells that persists in prostate cancer tissue. This finding suggests that the presence of these cells can predict patient responses to treatment and may help tailor treatment for different subgroups of patients.
A study found that 1/3 of cancer drugs with accelerated approval fail to show clinical benefit in post-approval trials yet remain recommended in clinical guidelines. Researchers call for reforms to improve clarity on FDA approvals and withdrawals.
A new study by UBC researchers found that chemotherapy drug cisplatin is more likely to cause hearing loss in young children, particularly those under five years old. The study, published in Cancer, shows that the hearing of these children is impacted early during treatment and is affected to a greater extent than older children.
PLOS Medicine features five studies outlining novel strategies for detecting cancer and identifying minimal residual disease. Researchers discuss innovative approaches, including plasma cell-free DNA sequencing and urine tumor DNA detection, to distinguish between benign and malignant tumors.
Silent mutations, which don't change protein sequences, hold diagnostic value in predicting cancer types and patient survival. The study analyzed over 10,000 cancer genomes and found that combining information from silent and non-silent mutations improved classification and prognostication up to 17% and 5%, respectively.
A research team has developed a cell printing technology to produce 3D cancer spheroids with varying diameters and blood vessels. This enables the reproduction of cancer metastasis properties, paving the way for personalized cancer treatments.
Researchers have developed a new photodynamic tumor therapy that works for deep tumors, eliminating the need for external irradiation. The 'intelligent' drug consists of four components linked into a single molecule that brings its own light source and switches it on in acidic tumorous tissue.
A modified chemotherapy regimen for Burkitt lymphoma has been developed, combining CODOX-M and IVAC with rituximab, to reduce toxicity and improve survival rates. The study found a higher overall survival rate and lower frequency of severe side effects compared to standard regimens.
Researchers used a comprehensive knowledgebase to identify 22 actionable genes and 43 candidate drugs for biliary tract cancer, which may lead to the development of targeted therapies. The study's findings contribute to personalized treatment options for this rare tumor worldwide.
Researchers from the University of South Australia are conducting a new study to understand what works well and what needs improvement in clinical trials for cancer patients. The study aims to identify barriers to trial participation and inform best practice, ultimately improving access to clinical trials and systems across Adelaide.
Researchers from St. Petersburg Electrotechnical University LETI propose a novel approach to cancer treatment using magnetic nanoparticles for targeted drug delivery. The method aims to minimize cytostatics' toxic effects on healthy tissues while maximizing accumulation in tumor tissue.
A recent study found that 20% of children with cancer infected with SARS-CoV-2 developed severe infections, compared to 1-6% in general pediatric patients. The Global Registry of COVID-19 and Childhood Cancer also showed that cancer care was disrupted, with 56% of patients having modified treatment and 45% having chemotherapy withheld.
A Phase 2 trial found that combining cisplatin, gemcitabine, and berzosertib did not prolong progression-free survival in patients with urothelial cancer. The study suggests that berzosertib may have a negative impact on bone marrow, leading to reduced white blood cells and platelets.